CoChat

Lobeglitazone, a Novel Thiazolidinedione, Improves Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Its Efficacy and Predictive Factors Related to Responsiveness

Open access
Lee, Yong-ho, Kim, Jae Hyeon, Kim, So Ra, Jin, Heung Yong, Rhee, Eun-Jung, Cho, Young Min, Lee, Byung-Wan · 2017 · Journal of Korean Medical Science
Cited by 104

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Despite the rapidly increasing prevalence of non-alcoholic fatty liver disease (NAFLD) in type 2 diabetes (T2D), few treatment modalities are currently available. We investigated the hepatic effects of the novel thiazolidinedione (TZDs), lobeglitazone (Duvie) in T2D patients with NAFLD. We recruited drug-naïve or metformin-treated T2D patients with NAFLD to conduct a multicenter, prospective, open-label, exploratory clinical trial. Transient liver elastography (Fibroscan®; Echosens, Paris, France) with controlled attenuation parameter (CAP) was used to non-invasively quantify hepatic fat contents. Fifty patients with CAP values above 250 dB/m were treated once daily with 0.5 mg lobeglitazone for 24 weeks. The primary endpoint was a decline in CAP values, and secondary endpoints included changes in components of glycemic, lipid, and liver profiles. Lobeglitazone-treated patients showed significantly decreased CAP values (313.4 dB/m at baseline vs. 297.8 dB/m at 24 weeks; P = 0.016), regardless of glycemic control. Lobeglitazone improved HbA(1C) values (7.41% [57.5 mM] vs. 6.56% [48.2 mM]; P < 0.001), as well as the lipid and liver profiles of the treated patients. Moreover, multivariable linear regression analysis showed that hepatic fat reduction by lobeglitazone was independently associated with baseline values of CAP, liver stiffness, and liver enzymes, and metformin use. Lobeglitazone treatment reduced intrahepatic fat content, as assessed by transient liver elastography, and improved glycemic, liver, and lipid profiles in T2D patients with NAFLD. Further randomized controlled trials using liver histology as an end point are necessary to evaluate the efficacy of lobeglitazone for NAFLD treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3346/jkms.2017.32.1.60

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Research works printed but not linked: 29

  1. Wang, 2011, Lancet, 378, 815, 10.1016/S0140-6736(11)60814-3 · DOI · Paper page
  2. Yoo, 2015, Diabetes Metab J, 39, 10, 10.4093/dmj.2015.39.1.10 · DOI · Paper page
  3. Park, 2016, J Korean Med Sci, 31, 410, 10.3346/jkms.2016.31.3.410 · DOI
  4. Lee, 2014, PLoS One, 9, e107584, 10.1371/journal.pone.0107584 · DOI · Paper page
  5. Chalasani, 2012, Hepatology, 55, 2005, 10.1002/hep.25762 · DOI · Paper page
  6. Williams, 2011, Gastroenterology, 140, 124, 10.1053/j.gastro.2010.09.038 · DOI · Paper page
  7. Kim, 2014, J Clin Endocrinol Metab, 99, 1879, 10.1210/jc.2013-4133 · DOI
  8. Harrison, 2008, Gut, 57, 1441, 10.1136/gut.2007.146019 · DOI · Paper page
  9. Chon, 2016, Yonsei Med J, 57, 885, 10.3349/ymj.2016.57.4.885 · DOI
  10. Kim, 2013, Endocrinol Metab (Seoul), 28, 280, 10.3803/EnM.2013.28.4.280 · DOI
  11. Sasso, 2010, Ultrasound Med Biol, 36, 1825, 10.1016/j.ultrasmedbio.2010.07.005 · DOI · Paper page
  12. de Lédinghen, 2014, J Hepatol, 60, 1026, 10.1016/j.jhep.2013.12.018 · DOI · Paper page
  13. Corzo, 2013, Diabetes Metab J, 37, 395, 10.4093/dmj.2013.37.6.395 · DOI
  14. Kim, 2011, Clin Ther, 33, 1819, 10.1016/j.clinthera.2011.09.023 · DOI
  15. Kim, 2014, PLoS One, 9, e92843, 10.1371/journal.pone.0092843 · DOI · Paper page
  16. Jin, 2015, Diabetes Obes Metab, 17, 599, 10.1111/dom.12435 · DOI
  17. Kim, 2015, Diabetes Res Clin Pract, 110, e27, 10.1016/j.diabres.2015.09.009 · DOI
  18. Chon, 2014, Liver Int, 34, 102, 10.1111/liv.12282 · DOI · Paper page
  19. Claridge, 2011, Lancet, 377, 2179, 10.1016/S0140-6736(11)60962-8 · DOI
  20. Arab, 2014, World J Gastroenterol, 20, 12182, 10.3748/wjg.v20.i34.12182 · DOI
  21. Sanyal, 2004, Clin Gastroenterol Hepatol, 2, 1107, 10.1016/S1542-3565(04)00457-4 · DOI · Paper page
  22. Musso, 2010, Hepatology, 52, 79, 10.1002/hep.23623 · DOI · Paper page
  23. Lupșor-Platon, 2015, J Gastrointestin Liver Dis, 24, 35, 10.15403/jgld.2014.1121.mlp · DOI
  24. Shen, 2014, World J Gastroenterol, 20, 4702, 10.3748/wjg.v20.i16.4702 · DOI
  25. Masaki, 2013, Hepatol Res, 43, 1182, 10.1111/hepr.12094 · DOI
  26. de Lédinghen, 2016, J Gastroenterol Hepatol, 31, 848, 10.1111/jgh.13219 · DOI · Paper page
  27. Bi, 2014, Acta Diabetol, 51, 865, 10.1007/s00592-014-0638-3 · DOI
  28. Koenen, 2009, J Clin Endocrinol Metab, 94, 4453, 10.1210/jc.2009-0517 · DOI · Paper page
  29. Musso, 2012, Diabetologia, 55, 885, 10.1007/s00125-011-2446-4 · DOI · Paper page

Cited by

Metadata

Authors
Lee, Y.-H., Kim, J. H., Kim, S. R., Jin, H. Y., Rhee, E.-J., Cho, Y. M., & Lee, B.-W.
Venue
Journal of Korean Medical Science
Publisher
XMLink
Published
2017
Volume
32
Issue
1
Pages
60
ISSN
  • 1011-8934 (ISSN-L)
  • 1598-6357
OpenAlex
W2555612317
Cited by
104
References
6
FWCI
6.54
Type
journal article
Language
en
Open access
gold
Licence
creativecommons.org/licenses/by-nc/4.0/ (tdm)
Funders
Chong Keun Dang, Pharmaceutical Co.

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.